Marostica E., Ahsman M., Bragt van T., Noukens J., Vis P., T’joen C., Ulrichts P., Guglietta A., Rossenu S., Steeg van T. Population analysis of MG-ADL total score for efgartigimod Phase 3 study in myasthenia gravis patients: application of a bounded-integer model. PAGE 2024 [Link to publication]
Vendel E., Noort van N., Vis P., Liefaard L., Dimelow R. Belimumab Pharmacokinetic Simulations to Select an Appropriate Subcutaneous Dosing Regimen to Treat Paediatric Patients with Active Lupus Nephritis. PAGE 2024 [Link to publication]
Marostica E., Ahsman M., Van Bragt T., Noukens J., T’joen C., Ulrichts P., Vis P., Rossenu S., Steeg van T. Population PK/PD analysis for efgartigimod Phase 3 study in myasthenia gravis patients. PAGE 2023 [Link to publication]
Berg van der P, Gao W, Ahsman M.J, Arrington L, Kesisoglou F, Miller R, Post T.M, Rizk M.L. Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development. CPT Pharmacometrics Syst Pharmacol. 2021 May 2. doi: 10.1002/psp4.12644. Epub ahead of print. PMID: 33934558.…
Bukkems V. E., Post T. M., Colbers A. P., Burger D. M., Svensson E. M. A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200mg in pregnant women living with HIV. CPT Pharmacometrics Syst. Pharmacol.(December 2020): 1–12, 2020. [Link to publication]
Berg P.v.d., Post T.M., Gao W., Miller R., Kesisoglou F., Arrington L., Rizk M.L. Application of a MK-3682 minimal PBPK-PD model to explain discrepancy between enhanced efficacy and PK in the presence of itraconazole. ACoP9, 2018.
Berg P.v.d., Post T.M., Gao W., Miller R., Kesisoglou F., Arrington L., Rizk M.L. An HCV nucleoside inhibitor MK-3682 minimal PBPK-PD model for application in hypothesis generation regarding metabolic pathways and perturbations under various conditions. PAGE, 2018. [Link to publication]
Maanen E.v., deJongh J. and Vis P., Gap identification as a critical step to enable integrated clinical trial simulation platforms; application to TB. joint Critical Path, FDA en ISoP meeting.(2013)
Maanen E.v., deJongh J. and Vis P., Cap identification as a critical step to enable integrated clinical trial simultaion platforms; Application to TB. Critical PAth for Tuberculosis Research Workshop.(2013)
Bergmann K., Ackaert O., Haddish-Berhane N. and Betts A., Comparing a mechanistic with an empirical approach to assess resistance development of antibacterials in vitro., PAGE.(2012) [Link to publication]